SMI 12?087 0.1%  SPI 15?534 0.1%  Dow 35?085 0.4%  DAX 15?640 0.5%  Euro 1.0773 -0.1%  EStoxx50 4?117 0.3%  Gold 1?828 1.2%  Bitcoin 36?010 -1.1%  Dollar 0.9062 -0.4%  Öl 75.9 1.5% 

AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

Seite 1 von 21
neuester Beitrag: 24.07.21 14:09
eröffnet am: 06.01.14 21:53 von: Masterbroker. Anzahl Beiträge: 509
neuester Beitrag: 24.07.21 14:09 von: Vassago Leser gesamt: 104628
davon Heute: 67
bewertet mit 4 Sternen

Seite: Zurück 1 | 2 | 3 | 4 |
19 | 20 | 21 | 21  Weiter  

06.01.14 21:53
4

3007 Postings, 2772 Tage MasterbrokerUSAAMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

Nächste Rakette ???  
Seite: Zurück 1 | 2 | 3 | 4 |
19 | 20 | 21 | 21  Weiter  
483 Postings ausgeblendet.

10.01.21 02:32

1383 Postings, 203 Tage NatalesaLöschung


Moderation
Zeitpunkt: 10.01.21 11:55
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Erotischer Inhalt

 

 

11.01.21 04:35

1082 Postings, 202 Tage CarolletaLöschung


Moderation
Zeitpunkt: 11.01.21 07:22
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Erotischer Inhalt

 

 

12.01.21 04:40

740 Postings, 200 Tage CastelicaLöschung


Moderation
Zeitpunkt: 12.01.21 07:36
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Erotischer Inhalt

 

 

13.01.21 01:50

1221 Postings, 199 Tage MobiannaLöschung


Moderation
Zeitpunkt: 13.01.21 07:48
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Erotischer Inhalt

 

 

10.02.21 08:17
1

2168 Postings, 4531 Tage MagnetfeldfredyAmarin

Nach der EU-Zulassungsempfehlung nun auch China und Honkong, Übernahme?


Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong

Amarin Corporation plc
Tue, February 9, 2021, 1:00 PM

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosapent ethyl) into commencement of the regulatory review processes in Mainland China and Hong Kong.

In Mainland China, the Chinese National Medical Products Administration (NMPA) has accepted for review the new drug application (NDA) for VASCEPA. Edding is seeking labeling based on the entirety of clinical data available for VASCEPA, including the previously announced successful results of the Phase 3 study conducted by Edding as well as studies conducted by Amarin. Edding currently anticipates receiving a decision in Mainland China near the end of 2021.

In Hong Kong, on a separate track, the Hong Kong Department of Health is evaluating VASCEPA based on current approvals in the United States and Canada. The review process in Hong Kong is anticipated to conclude near the end of 2021.

?We congratulate our partner, Edding, on the advancements made in the regulatory submission and review processes of VASCEPA in Mainland China and Hong Kong,? stated Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. ?The progress made is important for our vision of offering the unique benefits of VASCEPA to at-risk patients throughout the world. We look forward to the potential of introducing, through Edding, this important treatment option in Mainland China and Hong Kong.?

?We are very glad to know that the applications for drug approval of VASCEPA were formally accepted by the National Medical Products Administration (NMPA) in Mainland China and the Department of Health in Hong Kong,? stated James He, chief medical officer, Edding. ?Prevention and treatment of cardiovascular disease (CVD) is one of the major initiatives promoted by Health China 2030. However, few new CVD medications other than statins were launched in the market during the past several decades. In November 2020, Edding announced the positive, statistically significant top-line results of the Phase 3 clinical trial conducted in Mainland China. We will continue working with Amarin to bring this cross-era innovative drug into China to benefit Chinese patients.?

About Amarin
Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

About REDUCE-IT®
REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.1 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.2 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.3 These and other publications can be found in the R&D section on the company?s website at www.amarincorp.com.U  

25.02.21 15:29

7986 Postings, 1507 Tage VassagoAMRN 7.30$

Zahlen für Q4/20 und FY20

  • Umsatz 167 / 614 Mio. $
  • Ergebnis +5 / -18 Mio. $
  • Cash 563 Mio. $
  • MK 2,8 Mrd. $

https://investor.amarincorp.com/news-releases/...-year-2020-financial

 

17.03.21 17:01
1

2168 Postings, 4531 Tage MagnetfeldfredyAmarin mit Wunderwaffe Vascepa gegen Schlaganfall

Alleine dies Meldung müsste Vascepa Zweistellig machen, unglaublich gute Wirkung:

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

Amarin Corporation plc
Wed, March 17, 2021, 4:30 PM

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk

Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups

Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction

REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., March 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® STROKE at the International Stroke Conference 2021, being held virtually from March 17 ? March 19, 2021, adding to the growing body of knowledge on the clinical impact of VASCEPA® (icosapent ethyl). These new analyses supported by Amarin were presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women?s Hospital, Harvard Medical School, Boston, MA.

?The REDUCE-IT STROKE analyses provide important data supporting a new approach to prevent strokes using icosapent ethyl in appropriate patients,? commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women?s Hospital, Professor of Medicine at Harvard Medical School, and principal investigator of REDUCE-IT. ?The findings of benefit in at-risk patients include significant reductions in overall strokes and in ischemic strokes. Importantly, with respect to safety, we did not observe any significant increase in hemorrhagic stroke. These results further strengthen the case for pure eicosapentaenoic acid (EPA) in the form of prescription icosapent ethyl as a key intervention beyond statins for stroke prevention in studied patients.?

The REDUCE-IT STROKE analyses examined stroke rates across the enrolled patient population (n=8179). Enrolled patients were required to be treated with statins and other conventional therapies, and all patients had either established cardiovascular disease or diabetes and had other cardiovascular risk factors such as elevated triglyceride levels. Event rates for time to first fatal or nonfatal stroke were 2.4% for VASCEPA vs. 3.3% for placebo for a relative risk reduction (RRR) of 28% (p=0.01). Ischemic stroke time to first event rates were 2.0% for VASCEPA vs. 3.0% for placebo for a RRR of 36% (p=0.002). Hemorrhagic stroke occurred at low rates with no significant difference for VASCEPA vs. placebo (0.3% vs 0.2%; p=0.55).

Stroke is a major and often debilitating cardiovascular event significantly impacting not only patients and their loved ones, but also the healthcare system. Patients with elevated triglycerides despite statin therapy have increased risk for stroke-related events. Each year in the United States, about 795,000 people experience a new or recurrent stroke. Approximately 610,000 of these are first strokes, and 185,000 are recurrent strokes, or approximately 1 stroke every 40 seconds.1 The latest statistical update from the American Heart Association (AHA) shows that in the United States, the annual cost of stroke is $49.8 Billion.2

?Strokes significantly impact the healthcare system, driving substantial immediate and long-term costs,? said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. ?The subgroup data presented at ISC 2021 provide new insight into the unique potential benefits of VASCEPA administration on alleviating the societal burden of strokes.?

The REDUCE-IT STROKE abstract received the prestigious Paul Dudley White International Scholar Award, recognizing the authors with the highest ranked abstract across the United States at the International Stroke Conference 2021. The esteemed Paul Dudley White Award is named in honor of one of Boston?s most revered cardiologists, Dr. Paul Dudley White, who was a founding father of the American Heart Association and an early leader in preventive cardiology.

REDUCE-IT was designed and powered for the primary composite endpoint, of which stroke was one of five prespecified components; it was not powered for subgroup analysis. Stroke was a prespecified secondary endpoint within the testing hierarchy; ischemic stroke was a prespecified tertiary endpoint; stroke subgroup analyses were post hoc. No information was collected on stroke related disability, such as Rankin scores.

Brigham and Women?s Hospital receives research funding from Amarin for Dr. Bhatt?s work as the REDUCE-IT study Chair.

Additional information on ISC 2021 can be found here.

About Amarin

Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

About Cardiovascular Risk
The number of deaths in the United States attributed to cardiovascular disease continues to rise. There are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds), in the United States. Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. Cardiovascular disease results in 859,000 deaths per year in the United States.1 In aggregate, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, one every 13 seconds in the United States alone.

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient?s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.3 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.4,5,6  

20.03.21 20:59

1706 Postings, 2807 Tage GurkenheiniAmarin noch unbekannt

Stellt euch mal vor Amarin ist bei 95 Prozent der Ärzte noch relativ unbekannt,und machen über 600 Millionen Umsatz,wenn die in ein paar Monate bekannter werden und die Zullassung auch noch in Europa kommt,dann werden weltweit Milliarden verdient, und das jedes Jahr.Deshalb bin ich hier langfristig investiert und werde langfristig mein Bestand erhöhen.Für mich ist die Aktie stark unterbewertet.
 

30.03.21 16:13

7986 Postings, 1507 Tage VassagoAMRN 6.47$ (+5%)

EU Zulassung für Vazkepa

"The European approval provides 10 years of market protection for Vazkepa in the European Union," John Thero, Amarin?s president and chief executive officer, said in a statement.


https://investor.amarincorp.com/news-releases/...roval-vazkepa-reduce

 

13.04.21 19:29

7986 Postings, 1507 Tage VassagoAMRN 5.05$ (-14%)

13.04.21 20:03
1

567 Postings, 2319 Tage RV10Der ceo verlässt das sinkende schiff #haha

22.04.21 10:40

2168 Postings, 4531 Tage MagnetfeldfredyAmarin

Das sinkende Schiff, dass ich nicht lache!

Der CEO war der Hemmschuh, wollte nie eine Patnerschaft, Übernahme....

Vascepa ist eine Wunderwaffe gegen Schlaganfall, Herzinfarkt und jetzt mit EU-Zulassung ein Blockbuster der keine Generika wie in USA fürchten muß!

Hirn einschalten bevor man postet :

Billionaire Steve Cohen?s Top 10 Small-Cap Stock Picks

Ruchi Gupta
Wed, April 21, 2021, 7:18 PM

In this article we presented billionaire Steve Cohen's top 10 small-cap stock picks. You can skip our detailed discussion on Cohen's investment philosophy and read Billionaire Steve Cohen's Top 5 Small-Cap Stock Picks.

Steve A. Cohen is the owner of Point72 Asset Management, one of the most successful hedge funds in the U.S. He started off his Wall Street career as a junior trader at Gruntal & Co., where he dealt with options arbitrage. Cohen started his first hedge fund known as S.A.C. Capital Advisors in 1992, enjoying some success which allowed him to own 8 percent of Major League Baseball team, the New York Mets. He has also been involved in philanthropic causes in which he contributed $715 million.

Unfortunately, SAC Capital was allegedly involved in an insider trading scandal which led to a hefty $1.8 billion fine, and Cohen had to shut down the fund. This pave the way for the birth of his current hedge fund.
Point72 Asset Management

This is Cohen?s current hedge fund, based in Stamford. It has 17 clients, and its core strategy is long/short equity with investments in various asset classes across the globe. It has a particular focus on systematic, long/short, macro, and discretionary long/short strategies. The hedge fund attributes its success to the following:

   Macro insights and highlights

   Sector-aligned model

   Multi-manager platform

   A fundamental bottom-up research culture

   Focus on multiple asset classes

Portfolio percentage

The fund has 10.5% of its portfolio invested in communications industry, 21.8% in healthcare was, 18.9% in information technology, 14.48% in consumer discretionary, and 14.74% in finance.
Point72 Asset Management?s performance highlights

The hedge fund?s market value in Q4 2020 was $20.5 billion, a notable improvement from the Q3 2020 market value of $19.53 billion. The performance in the last four quarters was up 35.28%. In comparison, the hedge fund gave a return of 14.9% net of fees in 2019. Point72 Asset Management added 357 new stocks to its portfolio and purchased additional shares in 216 stocks. The hedge fund also reported that 376 stocks were sold out. It also reduced its holdings in 287 stocks.

Some of the stocks at the top of Point72 Asset Management?s portfolio include Alphabet Inc. (NASDAQ: GOOG), Advanced Micro Devices, Inc. (NASDAQ: AMD), SPDR S&P 500 ETF Trust (NYSE: SPY), Facebook, Inc. (NASDAQ: FB), Visa Inc. (NYSE: V), Microsoft Corporation (NASDAQ: MSFT), AstraZeneca PLC (NASDAQ: AZN), Uber Technologies, Inc. (NYSE: UBER), Dell Technologies Inc. (NYSE: DELL), and SPDR S&P Biotech ETF (NYSE: XBI).

Cohen is an exception in an industry that is reeling from losses. The entire hedge fund industry is feeling the reverberations of the changing financial landscape. Its reputation has been tarnished in the last decade, during which its hedged returns couldn?t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey?s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 124 percentage points since March 2017. Between March 2017 and February 26th 2021 our monthly newsletter?s stock picks returned 197.2%, vs. 72.4% for the SPY. Our stock picks outperformed the market by more than 124 percentage points (see the details here). We were also able to identify in advance a select group of hedge fund holdings that significantly underperformed the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 13% through November 16th. That?s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks

Let's take a look at Steve Cohen's top 10 small-cap stock picks by analyzing his Q4'2020 portfolio.
Best Small-Cap Stocks to Buy According to Billionaire Steve Cohen
10. At Home Group Inc. (NYSE: HOME)

Number of Hedge Fund Holders: 31

At Home Group owns home décor stores that sell wall décor, home furniture, furnishings, houseware, rugs, and decorative accents. At Home Group sells its products across the U.S. CAS Investment Partners was the largest hedge fund investor with 10.4 million shares.

   At Home Group reported a $1.08 non-GAAP EPS in Q4 2020, which was $0.38 more than the consensus estimate. Its GAAP EPS was $1.08, which was higher than the consensus estimates by $0.44.

   The company's revenue for the quarter was $561.99 million, which outperformed the consensus estimate by $36.18 million and represented a 41.3% gain YOY.

   At Home Group's adjusted EBITDA in Q4 2020 was $119.6 million, representing a 94.4% increase.

As of the end of the fourth quarter, 31 hedge funds in Insider Monkey?s database of 887 funds held stakes in HOME, compared to 34 funds in the third quarter. Clifford A. Sosin's CAS Investment Partners is the biggest stakeholder in the company, with 10.4 million shares, worth $161.3 million.

Bonhoeffer Capital Management, in their Q4 2020 investor letter, said that At Home Group Inc. (NYSE: HOME)?s current opportunity for organic growth is high. Here is what Bonhoeffer Capital Management has to say about At Home Group Inc. in their Q4 2020 investor letter:

   "At Home (HOME) is a home décor retailer. At Home provides home accessories (rugs, housewares, furniture, wall hangings, etc.) in a self-service format similar to Costco. The company has 219 stores in 40 states across the United States. The average size of an At Home store is 105,000 square feet offering over 50,000 SKUs. This is larger than other home décor retailer whose average store size is about 25,000 square feet. They also lease second-generation real estate resulting in a lower lease cost (average $6/ft2) than competitors. In Rochester, At Home is an old grocery location (the number two grocer in Rochester) which they have upgraded to remove the ?grungy? grocer appearance.

   The company?s value proposition is to provide a wide selection of goods at a low price point ($15 per item and less than $70 per basket). The stores have limited staff to support the self-service environment. In visits to local stores, At Home focuses on areas like carpets, barstools/seats, and wall decor of which other retailers have limited selections. Over 70% of the At Home merchandise is exclusive to At Home; so At Home can make both the retail and branded product margins for these products.

   At Home is not the largest competitor in the home décor market. Much of home décor is sold by generalists such as Walmart, Target, Home Depot, Amazon, and Lowe?s. These firms have 35% of the home décor market. At Home is a home décor specialty store like HomeGoods (owned by TJ Maxx), Williams Sonoma, and Bed Bath & Beyond. The market is quite competitive and players who have not been able to generate profitability have gone bankrupt, including Pier 1, with 1,500 stores nationwide. At Home has also pivoted to provide ?buy online, pick up in store? (BOPIS) during COVID to ensure sales continue despite the pandemic.

   Why Do Customers Keep Coming Back?

   Retailers who do not have recurring revenue can create recurring revenue by ensuring customers have a reason to return to the store or website. This brings to mind a local store in Rochester, Wegmans, that makes the shopping experience pleasurable and provides a wide selection of grocery items. The wide selection brings folks in, and the experience keeps them coming back. [read complete letter here]

9. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)

Number of Hedge Fund Holders: 24

This is a biopharma that develops immunosuppressive treatments. The stock jumped earlier this year after the company received FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis, a rare disease that affects about a third of people diagnosed with systemic lupus erythematosus. Investment firm Cantor Fitzgerald expects the treatment to deliver over $00 million in sales for the company.

Healthcor Management LP currently owns 6.9 million shares of AUPH, worth $95.9 million. AUPH occupies 3.7% of Healthcor?s overall equity.
8. Boot Barn Holdings, Inc. (NYSE: BOOT)

Number of Hedge Fund Holders: 20

It is one of the leading retailers in the U.S, with a robust portfolio of products that include apparel, footwear, and accessories for adults and children regardless of gender. It offers both lifestyle and work-related products from numerous brands. Boot Barn has 266 stores distributed across 36 states and an e-commerce website called bootbarn.com.

   Boot Barn Q3 2020 financials revealed that it underperformed its top and bottom lines.

   It reported a gross profit of $106.8 million from the previous $97 million, while its margin increased from 34.2% to 35.3%.

   Net sales were reported at $302.3 million, representing 6.5%. Same-store sales were up 4.6%, largely aided by the impressive 16.3% improvement in e-commerce sales, which overshadowed the meager 1.9% increase in same-store sales.

   Boot Barn?s operating income was $41.6 million, representing a 19% gain while margin improved from 12.5% to 13.8% during the quarterly period. The company?s net income for the same period was $29.6 million, an improvement from the $24.8 million reported in the previous quarter.

   The company had $76.3 million in cash and cash equivalents at the end of the quarter.

   Boot Barn CEO, Jim Conroy acknowledged the 150-basis-point improvement in the company's operating margin, which he believes aligns with the growth observed in same-store sales.

Boot Barn's performance during its fiscal Q3 2020 validates its inclusion in Steve Cohen's top 10 small-cap stocks list.

Israel Englander's Millennium Management currently holds 519,273 shares of Boot Barn that amounts $22.5 million. BOOT occupies 0.01% of Millennium Management?s total portfolio. Boot Barn attracted 20 hedge fund investors in Q4 2020, which was higher than 13 hedge funds in Q3 2020.
7. Amarin Corporation plc (NASDAQ: AMRN)

Number of Hedge Fund Holders: 24

Amarin Corporation plc (NASDAQ: AMRN) is an Ireland-based company that develops and sells medicines for the treatment of cardiovascular disease. One of the products that the company offers is the drug Vascepa, a prescription grade omega-3 fatty acid that competes against similar drugs made by bigger biotech firms. Amarin sells the medicines it makes to wholesale dealers and pharmacy providers. It was founded in 1989 and is placed first on our list of 10 best biotech stocks under $6 in 2021.

The firm is in partnership with Mochida Pharmaceutical Co., Ltd. to develop and sell drug products based on Vascepa. The Irish firm posted an annual revenue of more than $600 million in December 2020. Amarin was previously known as Ethical Holdings plc but changed the name to Amarin Corporation plc in 1999. Out of the hedge funds being tracked by Insider Monkey, New York-based Baker Bros. Advisors hold the most shares in the firm ? 27.9 million ? worth more than $136 million. Eversept Partners was second with shares worth $78 million.
6. Knowles Corporation (NYSE: KN)

Number of Hedge Fund Holders: 27

It is one of the leading global players in the manufacture of precision device solutions and advanced micro-acoustic audio processing. Some of its markets include the communications, consumer mobile, automotive, defense, medtech, and industrial segments. The company leverages its advantageous position in advanced audio processing and MEMS (micro-electro-mechanical systems) microphones to enhance user experience in IoT, ear, and mobile applications.

Knowles Corp is also one of the leading authorities in mmWave RF, high-end capacitors, and acoustic components. This makes it a key player in supplying important components for technologies such as 5G, strategic for growth.

   Knowles reported a $0.41 non-GAAP EPS in Q4 2020, outperforming the consensus EPS estimate by $0.04. Its GAAP EPS for the same period was $0.32, outperforming the estimate by $0.02.

   The company's revenue for the quarterly period was $243.2 million, representing a 4.0% gain year-over-year.

As of the end of the fourth quarter of 2020, John W. Rogers' Ariel Investments owns 4.6 million shares of Knowles Corp. worth $85.7 million. KN accounts for 0.96% of Ariel Investments' total portfolio. There were 27 hedge funds that realized KN's potential and invested in the company in the fourth quarter of 2020.  

24.04.21 02:27

9 Postings, 96 Tage InestvpoaLöschung


Moderation
Zeitpunkt: 24.04.21 10:24
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

24.04.21 13:24

10 Postings, 96 Tage BarbaracwewaLöschung


Moderation
Zeitpunkt: 25.04.21 00:11
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: -

 

 

25.04.21 03:19

9 Postings, 95 Tage BirgitakfraLöschung


Moderation
Zeitpunkt: 26.04.21 10:23
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

25.04.21 10:04

10 Postings, 95 Tage JaninafpmzaLöschung


Moderation
Zeitpunkt: 26.04.21 11:51
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer, Beitrag wird nicht mehr angezeigt.
Kommentar: Spam

 

 

29.04.21 16:34

7986 Postings, 1507 Tage VassagoAMRN 5.37$ (+4%)

Zahlen für Q1/21

  • Umsatz 142 Mio. $
  • Verlust 2 Mio. $
  • Cash 539 Mio. $
  • MK 2,1 Mrd. $

Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021

https://investor.amarincorp.com/news-releases/...results-and-provides

 

13.05.21 13:57

7986 Postings, 1507 Tage VassagoAMRN 4.35$ (-6%)

Die GS-Abstufung von neutral auf sell mit der Anpasung des Kursziels von 6 auf 5$ ist maximal am Rande erwähnenswert.
https://www.fool.com/investing/2021/05/12/...stock-is-tumbling-today/

Viel interessanter sind die angeblichen Praktiken mit den Amarin versuchen soll die Konkurrenz zu behindern. Es geht um Exklusivverträge mit Lieferanten und das angebliche "Horten von Icosapent-Ethyl-API-Produkten".

https://www.competitionpolicyinternational.com/...eneric-drug-delays/  

21.06.21 16:21

7986 Postings, 1507 Tage VassagoAMRN 4.52$ (-9%)

  • der Oberste Gerichtshof der USA lehnt das "Angebot" von Amarin ab, die Arzneimittelpatente von Vascepa wiederzubeleben

https://www.bnnbloomberg.ca/...id-to-revive-vascepa-patents-1.1619692


 

21.06.21 16:51
1

567 Postings, 2319 Tage RV10Damit ist 1$ unausweichlich

24.07.21 14:09

7986 Postings, 1507 Tage VassagoAMRN 4.02$

Seite: Zurück 1 | 2 | 3 | 4 |
19 | 20 | 21 | 21  Weiter  
   Antwort einfügen - nach oben